Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,123 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (356)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07404566 | Utility of MicroRNAs for Diagnosing Hepatocellular Carcinoma in Hepatitis C Patients | completed | — | 84 | Benha UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03211416 | Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | completed | Phase 1 / Phase 2 | 37 | Roswell Park Cancer InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03713593 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | completed | Phase 3 | 794 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Feb 5, 2026 | clinicaltrials |
| NCT07386639 | Sex-Specific Machine Learning Models to Predict Distant Metastasis in Liver Cancer(GENDER-HCC-MET) | completed | — | 19,019 | Tongji UniversityOTHER | 0 | Feb 4, 2026 | clinicaltrials |
| NCT06310590 | Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma | completed | Phase 1 | 40 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT01730937 | Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | completed | Phase 3 | 193 | Radiation Therapy Oncology GroupNETWORK | 5 | Jan 28, 2026 | clinicaltrials |
| NCT06631326 | HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) | completed | — | 244 | First Hospital of China Medical UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07368530 | Using Machine Learning to Identify Responders to TACE or HAIC for uHCC | completed | — | 3,000 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05166239 | HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT | completed | Phase 2 | 66 | Peking UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05641896 | Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers(18F-FAPI-74 GI) | completed | Phase 2 | 109 | SOFIEINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07349576 | Precision Dietary Intervention Improves Postoperative Energy Intake, Nutritional Status, and Recovery in Patients Undergoing Hepatectomy for Liver Cancer: A Randomized Controlled Trial | completed | N/A | 139 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05349331 | Watch and Wait and Surgical Treatment for Clinical Complete Responders After Non-Curative Therapy for Hepatocellular Carcinoma(WATCH) | completed | Phase 2 | 74 | Sun Yat-sen UniversityOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05337137 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer(RELATIVITY-106) | completed | Phase 1 / Phase 2 | 83 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 12, 2026 | clinicaltrials |
| NCT04459468 | Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC | completed | — | 17 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04567615 | A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | completed | Phase 2 | 266 | Bristol-Myers SquibbINDUSTRY | 17 | Jan 8, 2026 | clinicaltrials |
| NCT07321613 | Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients | completed | — | 545 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03199274 | Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer | completed | Phase 2 | 104 | Thomas Jefferson UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05100082 | Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma | completed | — | 263 | TakedaINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer(CheckMate040) | completed | Phase 1 / Phase 2 | 657 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 24, 2025 | clinicaltrials |
| NCT04862949 | Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC | completed | — | 131 | CHA UniversityOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04798781 | Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma | completed | Phase 2 | 16 | Andrew Hendifar, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03071458 | Mutational Landscape in Hepatocellular Carcinoma(MUTHEC) | completed | — | 808 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07272265 | The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study | completed | N/A | 300 | Sun Yat-sen UniversityOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT03963206 | Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)(CLERANCE) | completed | Phase 4 | 110 | Hospices Civils de LyonOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05384184 | Next Generation " Pre-clinical Model for Colorectal Cancer Metastases and Hepatocellular Carcinomas(BORG) | completed | — | 48 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04828486 | Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer | completed | Phase 2 | 14 | Mayo ClinicOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06294808 | Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC | completed | — | 1,043 | National Cancer Centre, SingaporeOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07153783 | Interventional AI-Human Collaboration for Liver Tumor Diagnosis | completed | N/A | 10,333 | Shengjing HospitalOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05622071 | Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions(HESTIA) | completed | Phase 2 | 50 | UNICANCEROTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04874519 | Registry to Collect Health Information Related to Fibrolamellar Cancer | completed | — | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT00183885 | A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 76 | University of Southern CaliforniaOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05091346 | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 89 | Eisai Inc.INDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03412773 | A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 3 | 684 | BeiGeneINDUSTRY | 11 | Oct 14, 2025 | clinicaltrials |
| NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | completed | Phase 1 | 31 | MacroGenicsINDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT02799212 | Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma(SOMAPROTECT01) | completed | Phase 3 | 179 | Hospices Civils de LyonOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT03062358 | Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) | completed | Phase 3 | 453 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Sep 30, 2025 | clinicaltrials |
| NCT06230328 | Brazilian Reality of Hepatocellular Carcinoma(BRA-HEP) | completed | — | 300 | AstraZenecaINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04487067 | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista(AMETHISTA) | completed | Phase 3 | 152 | Hoffmann-La RocheINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06358001 | EchoTip AcuCore Post-Market Clinical Study | completed | — | 183 | Cook Research IncorporatedINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07184424 | Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC(Lenalidomide) | completed | N/A | 24 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04264260 | Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment | completed | Phase 2 | 42 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07160374 | ThinkRadial: A Prospective Study of Transradial deTACE in HCC Patients(ThinkRADIAL) | completed | — | 38 | Asan Medical CenterOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05197504 | Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy(HCC) | completed | — | 166 | CHA UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07157085 | AI Multitask Model for HCC Treatment | completed | — | 7,000 | Sun Yat-sen UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03037437 | Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer | completed | Phase 2 | 64 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07143955 | Dietary Intervention and Gut Microbiota in Hepatocellular Carcinoma (HCC) | completed | N/A | 100 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT03638141 | CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab | completed | Phase 2 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 17, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Feb 12, 2026source: clinicaltrials